Efficacy and Safety Study of Fluvastatin and Ezetimibe Combined Versus Fluvastatin Alone - Full Text View

Purpose

The objective of this study is to assess the effect of the combination treatment on C-reactive protein and inflammatory markers as well as the safety and tolerability in a Spanish population

Condition	Intervention	Phase
Dyslipidemia	Drug: fluvastatin, ezetimibe	Phase III

MedlinePlus related topics:

Cholesterol

Drug Information available for:

Ezetimibe Fluvastatin

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Official Title:	Efficacy and Safety Study of Fluvastatin and Ezetimibe Combined Versus Fluvastatin Alone

Further study details as provided by Novartis:

Primary Outcome Measures:

Change from baseline in low density lipoprotein cholesterol after 12 weeks

Secondary Outcome Measures:

Change from baseline in total triglyceride, high density lipoprotein cholesterol, and composition of low density lipoprotein cholesterol after 12 weeks
Change from baseline in circulating marker of inflammation after 12 weeks

Estimated Enrollment:	80
Study Start Date:	August 2003

Eligibility

Ages Eligible for Study:	18 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients aged 18-75 Primary hypercholesterolemia Signed informed consent

Exclusion Criteria:

Patients involved in clinical trials 3 months prior to inclusion Patients treated with drugs specified in protocol Fertile women not using contraceptive methods

Other protocol defined in and exclusion criteria may apply

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00171288

Locations


Spain
	Novartis
	Madrid, Spain

Sponsors and Collaborators

Novartis

Investigators


Study Director:	Novartis Pharmaceuticals	Novartis Pharmaceuticals

More Information

Study ID Numbers:	CXUO320BES03
First Received:	September 12, 2005
Last Updated:	March 20, 2008
ClinicalTrials.gov Identifier:	NCT00171288
Health Authority:	Spain: Spanish Agency of Medicines

Keywords provided by Novartis:

Dyslipidemia, ezetimibe, inflammatory markers, fluvastatin

Study placed in the following topic categories:

Metabolic Diseases

Ezetimibe

Metabolic disorder

Fluvastatin

Dyslipidemias

Lipid Metabolism Disorders

Additional relevant MeSH terms:

Antimetabolites

Molecular Mechanisms of Pharmacological Action

Therapeutic Uses

Antilipemic Agents

Enzyme Inhibitors

Anticholesteremic Agents

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Pharmacologic Actions

ClinicalTrials.gov processed this record on November 06, 2008

Sponsored by:	Novartis
Information provided by:	Novartis
ClinicalTrials.gov Identifier:	NCT00171288